Table 3.
Patient’s genomic landscape by circulating tumor DNA (ctDNA) sequencing
| Pt ID | Tumor Histology | DCB | TMB (mut/Mb) | NbVarCalls | Variant (gene; point mutation; variant allelic frequency; coverage) |
|---|---|---|---|---|---|
| 01 | Colorectal carcinoma | No DCB | 10,9 | 13 |
PIK3CA; p.Glu545Lys; 4%; 900X AKT1; p.Glu17Lys; 4%; 992X GNAS; p.Arg201His; 4%; 299X |
| 02 | Renal cell carcinoma | No DCB | 2,52 | 3 | NA |
| 03 | Cervical cancer | DCB | 2,52 | 3 | DNMT3A; p.Phe521SerfsTer24; 25%; 1023X |
| 04 | Gastric cancer | No DCB | 0,84 | 1 | NA |
| 05 | Undifferentiated carcinoma of nasopharyngeal type | DCB | 2,51 | 3 | NA |
| 06 | Cervical cancer | DCB | 0,84 | 1 | NA |
| 07 | Mesothelioma | No DCB | 5,05 | 6 |
PTEN; p.Tyr65Ter; 7%; 408X NOTCH1; p.[Gln2393His;Gln2394Ter]; 16%; 309X |
| 08 | Neuroendocrine tumor | No DCB | 3,35 | 4 |
KRAS; p.Gly12Asp; 25%; 449X TP53; p.Glu343Ter; 53%; 1533X |
| 09 | Triple Negative Breast Cancer | No DCB | 3,35 | 4 | TP53; p.Trp91Ter; 23%; 714X |
| 11 | Thymic carcinoma | DCB | 4,19 | 5 | NA |
| 12 | Thymic carcinoma | DCB | 5,03 | 6 |
CDKN2A; p.Val59AlafsTer79; 88%; 1212X TP53; p.Arg282Pro;66%; 1895X |
| 13 | Mesothelioma | No DCB | 3,32 | 4 | NA |